清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Abstract 1841: IMGC936, an investigational ADAM9-targeting antibody drug conjugate, is active against patient-derived ADAM9-expressing xenograft models

医学 癌症 抗体-药物偶联物 癌症研究 抗体 转移 人源化抗体 单克隆抗体 生物 免疫学 内科学
作者
Olga Ab,Juniper A. Scribner,Kerstin W. Sinkevicius,Deryk T. Loo,Stuart W. Hicks,Krystal Watkins,Francine Z. Chen,Christopher W. Espelin,Marian Themeles,Ying Li,Chet Bohac,Patrick Zweider McKay,Paul A. Moore,Callum Mortimer Sloss,Ezio Bonvini,Eric H. Westin
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:81 (13_Supplement): 1841-1841
标识
DOI:10.1158/1538-7445.am2021-1841
摘要

Abstract Background: A disintegrin and metalloprotease (ADAM) 9 is a member of the ADAM family of transmembrane proteins. ADAM9 overexpression correlates with tumor progression, metastasis and poor prognosis in multiple cancers. IMGC936, an ADAM9-targeting antibody drug conjugate (ADC), is comprised of a high-affinity humanized monoclonal antibody site-specifically coupled to DM21 at a drug-antibody ratio of 2.0. DM21 is a next-generation linker-payload that combines a maytansinoid microtubule-disrupting payload with a stable tripeptide linker. IMGC936 is in a phase 1 dose escalation study evaluating safety and pharmacokinetics in cancer patients. The goals of this study were: 1) to explore ADAM9 expression in various solid tumors, and 2) to evaluate the activity of IMGC936 in clinically relevant patient-derived xenograft (PDX) models with ADAM9 expression similar to that observed in human tumors. Methods: ADAM9 expression was evaluated on primary patient and PDX formalin-fixed, paraffin-embedded samples with the anti-ADAM9 antibody D64B5 (Cell Signaling Technology). Expression of ADAM9 was quantitated by H-score to capture the frequency and intensity of staining. Mice bearing PDX tumors were dosed once at 8.6 mg/kg of IMGC936, which delivered 100 µg/kg of DM payload. Anti-tumor activity was defined by NCI standards: median tumor volume of treated mice over control mice (%) > 42% (inactive), ≤ 42% (active), and <10% (highly active). Results and Conclusions: ADAM9 was highly expressed in multiple tumor types. A majority of the tumor samples had medium to high levels of ADAM9 with 62% of non-small cell lung carcinoma (NSCLC), 65% of triple negative breast cancer (TNBC), 73% of gastric cancer, and 85% of pancreatic cancer samples having H- scores of 101 to 300. The remaining tumor samples had lower levels of ADAM9 expression (H-score 1 to 100) with only 1.2% of NSCLC samples being ADAM9-negative. Activity of IMGC936 was analyzed in PDX models derived from NSCLC, TNBC, pancreatic and gastric cancers. The range of ADAM9 expression was 27 to 226 by H-score, with 80% of the samples having H-scores above 101. A single dose of IMGC936 at 8.6 mg/kg was well tolerated. Across the tumor types tested, IMGC936 was active or highly active in 24 out of 35 models (69%) with complete regressions in 6 models (4 NSCLC, 2 TNBC). The 24 IMGC936 sensitive models had H-scores between 65 and 224. The 11 non-sensitive models had H-scores between 27 and 226. The data suggest that factors independent of ADAM9 expression contribute to model sensitivity toward IMGC936 and warrant further biomarker exploration. These studies demonstrate that ADAM9 is highly expressed in a large number of solid tumor indications and show that IMGC936 has activity against multiple solid tumor types with a wide range of clinically relevant ADAM9 levels. These data support the clinical evaluation of IMGC936 (NCT04622774). Citation Format: Olga Ab, Juniper A. Scribner, Kerstin Sinkevicius, Deryk Loo, Stuart W. Hicks, Krystal Watkins, Francine Z. Chen, Christopher Espelin, Marian Themeles, Ying Li, Chet Bohac, Patrick Zweidler McKay, Paul A. Moore, Callum M. Sloss, Ezio Bonvini, Eric H. Westin. IMGC936, an investigational ADAM9-targeting antibody drug conjugate, is active against patient-derived ADAM9-expressing xenograft models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1841.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
5秒前
俭朴竺完成签到,获得积分10
11秒前
liangyao完成签到,获得积分20
13秒前
Tardes关注了科研通微信公众号
19秒前
21秒前
朴实惜寒完成签到,获得积分10
29秒前
11完成签到 ,获得积分10
29秒前
31秒前
king完成签到 ,获得积分10
36秒前
wsj完成签到 ,获得积分10
37秒前
Tardes发布了新的文献求助10
38秒前
ss完成签到,获得积分10
41秒前
甜美的梦芝完成签到,获得积分10
43秒前
西瓜柠檬可乐完成签到 ,获得积分10
58秒前
李煜琛完成签到 ,获得积分10
1分钟前
悦耳的竺完成签到 ,获得积分10
1分钟前
搜集达人的应助被冲冲冲采纳,获得10
1分钟前
大力的安阳完成签到 ,获得积分10
1分钟前
无花果的应助被ZLPY采纳,获得30
1分钟前
1分钟前
1分钟前
刘亚梅完成签到 ,获得积分10
1分钟前
醉熏的小凡完成签到,获得积分10
1分钟前
冲冲冲发布了新的文献求助10
1分钟前
apt完成签到 ,获得积分10
1分钟前
1分钟前
忧伤的白秋完成签到,获得积分10
1分钟前
1分钟前
lx完成签到 ,获得积分10
1分钟前
天天快乐的应助被hilufite采纳,获得10
1分钟前
nhzz2023完成签到 ,获得积分10
1分钟前
和谐如彤完成签到,获得积分10
1分钟前
nanjing01完成签到 ,获得积分10
1分钟前
如泣草芥完成签到,获得积分10
1分钟前
Jessie完成签到,获得积分10
1分钟前
RZH发布了新的文献求助50
2分钟前
hy发布了新的文献求助10
2分钟前
笙歌完成签到 ,获得积分10
2分钟前
点点完成签到 ,获得积分10
2分钟前
细胞呵呵完成签到 ,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173230
求助须知:如何正确求助?哪些是违规求助? 9565593
关于积分的说明 21780525
捐赠科研通 7767429
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555764
邀请新用户注册赠送积分活动 2476697